Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554248 | 0.83 | ENPP2 (0.31) | ENPP2 | |
| SCHEMBL13554239 | 0.77 | RXRA (0.33) | ENPP2 | |
| SCHEMBL29956646 | 0.76 | ENPP2 (0.46) | ENPP2TTRALDH1A1POLBMAPT | |
| SCHEMBL2854999 | 0.76 | ENPP2 (0.46) | ENPP2TTRALDH1A1POLBMAPT | |
| SCHEMBL29953019 | 0.73 | CSNK2A1 (0.44) | ENPP2TTRMEN1USP2ALDH1A1 | |
| SCHEMBL4881084 | 0.73 | CSNK2A1 (0.44) | ENPP2TTRMEN1USP2ALDH1A1 | |
| SCHEMBL23363515 | 0.72 | ENPP2 (0.43) | ENPP2TTRMEN1USP2ALDH1A1 | |
| SCHEMBL2561475 | 0.72 | L3MBTL1 (0.46) | ENPP2TTRMEN1USP2ALDH1A1 | |
| SCHEMBL29956963 | 0.72 | ENPP2 (0.43) | ENPP2TTRMEN1USP2ALDH1A1 | |
| SCHEMBL29956752 | 0.72 | ENPP2 (0.43) | ENPP2TTRMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | ENPP2 4417/4885TTR 3663/4885MEN1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.